Build your base

Alienum phaedrum torquatos nec eu, vis detraxit periculis ex, nihil expetendis in mei. Mei an pericula euripidis, hinc partem ei est.
Back to top

Dominik Karres, MD

New Horizon / Dominik Karres, MD

Dominik Karres, MD

Scientific Officer at European Medicines Agency


Dominik received his medical degree and MD in paediatric drug development from the University Erlangen/ Nuremberg (Germany) in 2007. He held a training post in Germany in paediatric haematology/ oncology (University Hospital Muenster) and worked in Germany and the UK (Royal Marsden Hospital/ Institute of Cancer Research UK) in paediatric oncology and paediatric oncology drug development. In 2014 he joined the UKs medicines regulatory agency (MHRA) with positions in the Licensing and Post-marketing Division as accredited assessor and national expert to the European Medicines Agency (EMA), before joining the EMAs Paediatric Medicines Office in 2018 as scientific office. Dominik is involved in product and regulatory science related aspects concerning paediatric oncology drug development. In this capacity he is also the EMAs nominee to the ACCELERATE Steering committee, a multi-stakeholder platform aiming to facilitate the acceleration of science driven developments of paediatric oncology drugs through global cooperation and collaboration. Dominik has (co)-authored several scientific articles and policy pieces in peer-reviewed journals on topics related to paediatric oncology drug development.


Oct 28th 10:30 AM ET Panelist Session 2 – Reaching Agreement with Regulators on Global Approach to Pediatric Drug Development